Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)
M
Marwan Ghabril
Primary Investigator
Enrolling By Invitation
18-85 years
All
Phase
3
466 participants needed
1 Location
Brief description of study
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter studyhe efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episodevert hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by thedically controlled ascites.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hepatic Encephalopathy
-
Age: Between 18 Years - 85 Years
-
Gender: All
Key Inclusion Criteria:
- Diagnosis of liver cirrhosis with medically controlled ascites (>30 days) notquiring therapeutic paracentesis (could have had paracentesis in the past).
- Conn (West Haven Criteria) score of < 2.
- Mini-Mental State Examination (MMSE) score > 24 at screening.
- ≥ 18 and ≤ 85 years of age.
Key Exclusion Criteria:
- Active COVID-19 that is unresolved
- History of SBP
- History of EVB or AKI-HRS within 6 months
- History of OHE episode (Conn score ≥ 2)
Updated on
01 Aug 2024.
Study ID: RNLC3131
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
